Skip Navigation

Lotus Pharmaceuticals Secures Three HR Asia Awards for 2024

05 July 2024

Taipei, Taiwan, July 5, 2024 — Lotus Pharmaceutical (“Lotus” or “the Company”, Taiwan TWSE ticker: 1795), a leading multinational pharmaceutical company, is thrilled to announce its remarkable success at the HR Asia Awards 2024, where it has been honored in three prestigious categories, recognizing its excellence in human resource management and commitment to employee well-being.


HR Asia Best Companies to Work for in Asia Taiwan 2024: Lotus Pharmaceuticals has once again been awarded the coveted "Best Companies to Work for in Asia" title by HR Asia. This accolade highlights Lotus's unwavering commitment to fostering an exceptional workplace environment, characterized by high employee satisfaction, ample growth opportunities, and a supportive corporate culture.


Diversity, Equity & Inclusion Awards 2024: The Diversity, Equity & Inclusion Award celebrates Lotus's proactive initiatives in promoting diversity and nurturing an inclusive workplace culture. By embracing a wide range of perspectives and talents from around the globe, Lotus continues to enhance its organizational resilience and innovative capabilities.


Most Caring Company Awards 2024: Lotus's dedication to employee well-being and community welfare has been recognized with the Most Caring Company Award. This honor reflects Lotus's compassionate initiatives and robust support systems that prioritize the holistic development and welfare of its workforce.


"We are deeply honored to receive these prestigious awards from HR Asia," said Petar Vazharov, Chief Executive Officer of Lotus Pharmaceuticals. "At Lotus, our people are our greatest asset. These awards validate our efforts in creating an inclusive, equitable, and supportive workplace where every employee can thrive and contribute to our mission of providing high-quality, affordable medicines globally."


Lotus Pharmaceuticals has experienced significant growth in recent years, evolving from a local pharmaceutical company specializing in generic drugs to an international industry leader. This transformation has been driven by a diverse workforce representing over 14 nationalities, contributing a rich tapestry of perspectives and skills to the organization.


The Company remains steadfast in its commitment to gender equality within its workforce, maintaining a balanced distribution of male and female employees across all organizational levels. This commitment is evident in leadership roles, where the ratio of male to female executives stands at 6:4, reflecting equal opportunities for career advancement and leadership development.


As Lotus Pharmaceuticals continues to expand its global footprint and impact in the pharmaceutical sector, it remains dedicated to upholding the highest standards of corporate governance, sustainability, and social responsibility.


About Lotus

Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with global presence, focused on commercializing novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines. The Company has a recognized best-in-class R&D and manufacturing platform in Asia and has established partnerships in nearly every global market including the U.S., Europe, Japan, China, and Brazil. Lotus runs over 100 strategically selected pharmaceutical projects in development and registrations across Asia and the US, with over 250 commercial products. The Company invests in diversified best portfolio consisting of high-barrier oncology, complex generics as well as 505(b)2 and NCE via internal R&D investment and licensing-in partnership, and also strengthens its portfolio competitiveness by adding biosimilar products with support from strategic partners. Its industry-leading infrastructure certified by most of the advanced regulatory authorities around the world, including US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA.

Media Inquiries:

Yu-ying Yang, Associate Director, Corporate Communication

+886 2 2700 5908